Caroline Chen

Reporter

Photo of Caroline Chen

Caroline Chen covers health care for ProPublica. Previously, she worked at Bloomberg News, where she wrote about Valeant Pharmaceutical’s use of a mail order pharmacy to boost reimbursements for its drugs, the tactics used by a rare disease drugmaker to scare patients into staying on therapy, and the plight of medically complex babies who get stranded in hospitals because of a lack of home-care nurses. She received her Master’s degree from the Stabile Program in Investigative Journalism at Columbia University, where she was awarded a Pulitzer Traveling Fellowship.

Citing “Safety Concerns,” FDA Cautions National Marketer of Unproven Stem Cell Treatments

This month, we reported R3 Stem Cell was promoting unapproved birth tissue products for a wide range of diseases. This week, the FDA put the company on notice.

The Birth-Tissue Profiteers

How well-meaning donations end up fueling an unproven, virtually unregulated $2 billion stem cell industry.

Black Patients Miss Out On Promising Cancer Drugs

A ProPublica analysis found that black people and Native Americans are under-represented in clinical trials of new drugs, even when the treatment is aimed at a type of cancer that disproportionately affects them.

A Cancer Patient’s Guide to Clinical Trials

If you’re considering whether to enroll in a trial of an experimental drug, here’s what you need to know.

Have You Donated or Helped to Collect Birth Tissue?

ProPublica is seeking your help in finding out how birth tissue donated by mothers is used in research and by industry.

Immigrant Shelters Drug Traumatized Teenagers Without Consent

Whether they came to the U.S. alone, or were forcibly separated from their families at the border, despondent minors are often pressured into taking psychotropic drugs without approval from a parent or guardian.

FDA Repays Industry by Rushing Risky Drugs to Market

As pharma companies underwrite three-fourths of the FDA’s budget for scientific reviews, the agency is increasingly fast-tracking expensive drugs with significant side effects and unproven health benefits.

Follow ProPublica

Latest Stories from ProPublica